November 2024, Cambridge, MA – Seasoned drug delivery executive, Steven Kaufman, to join Portal Instruments as their Chief Commercial Officer. Prior to joining Portal Instruments in November 2024, Steven held executive positions at Stevanato Group, Bespak and SHL Medical.
November, 2024 Cambridge, MA – Portal Instruments is pleased to announce that Steven Kaufman will be joining Portal Instruments as their interim Chief Commercial Officer.
Steven is a recognized leader in the device industry, having held numerous leadership roles related to Business Development, Product Management, Marketing and Strategy. Prior to joining Portal Instruments in November 2024, Steven held executive positions at Stevanato Group, Bespak and SHL Medical.
Patrick Anquetil, CEO, welcomed Steven, noting Steven's broad expertise in the area of self-injection devices and his proven track-record taking devices from design, development, manufacture, final assembly to clinical and then commercial launch in Europe, North America and APAC. "Steven's expertise in drug delivery will be a strong asset to Portal Instruments as we continue to move towards commercialization."
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
Portal Instrument's CEO, Dr. Patrick Anquetil, shares insights on reducing healthcare waste through reusable autoinjectors in a compelling OnDrug Delivery interview, "A Sustainable Future for Self-Injection with Connected, Reusable Autoinjectors."
May 9, 2022 - Gerresheimer AG, a leading provider of drug delivery systems, is expanding its portfolio of highly innovative platform technologies for drug delivery, today announcing an investment into US-based Portal Instruments.
Please fill out the details below and we will get back to you shortly.